Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated
Ramzi Abboud(Washington University in St. Louis), Rizwan Romee(Harvard University), Todd A. Fehniger(Washington University in St. Louis), Ravi Vij(Washington University in St. Louis), Kathryn Trinkaus(Washington University in St. Louis), Michael P. Rettig, John F. DiPersio(Washington University in St. Louis), Mark A. Schroeder(MACOM (United States)), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Camille N. Abboud(Washington University in St. Louis), Peter Westervelt(MACOM (United States)), Stéphanie Meier(Washington University in St. Louis), Jesse Keller(Washington University in St. Louis), Michael Slade(Washington University in St. Louis)
Cited by 164
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
|Immunity|2007|988
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783